Pages that link to "Q409587"
Jump to navigation
Jump to search
The following pages link to naltrexone (Q409587):
Displaying 50 items.
- Crohn's disease (Q1472) (← links)
- non-controlled substance abuse (Q182413) (← links)
- naloxone (Q282902) (← links)
- substance abuse (Q3184856) (← links)
- bupropion/naltrexone (Q4998036) (← links)
- opioid receptor mu 1 (Q5123372) (← links)
- Low-dose naltrexone (Q5259325) (← links)
- nalmexone (Q6961001) (← links)
- alcohol abuse (Q7331102) (← links)
- opioid receptor kappa 1 (Q8083989) (← links)
- Opioid receptor, kappa 1 (Q14900999) (← links)
- morphine/naltrexone (Q17126485) (← links)
- opiate dependence (Q18555117) (← links)
- Opioid receptor delta 1 (Q21115334) (← links)
- Opioid receptor, delta 1 (Q21988386) (← links)
- An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A (Q22000603) (← links)
- Naltrexone for cocaine dependence treatment (Q24188333) (← links)
- Low dose naltrexone for induction of remission in Crohn's disease (Q24200319) (← links)
- Low dose naltrexone for induction of remission in Crohn's disease (Q24201218) (← links)
- Naltrexone for cocaine dependence treatment (Q24234664) (← links)
- Oral naltrexone maintenance treatment for opioid dependence (Q24235092) (← links)
- Oral naltrexone maintenance treatment for opioid dependence (Q24236708) (← links)
- Sustained-Release Naltrexone For Opioid Dependence (Q24243205) (← links)
- Oral naltrexone maintenance treatment for opioid dependence (Q24244834) (← links)
- Sustained-Release Naltrexone For Opioid Dependence (Q24245720) (← links)
- Naltrexone maintenance treatment for opioid dependence (Q24248739) (← links)
- Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN) (Q24622752) (← links)
- Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study (Q24630189) (← links)
- Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence (Q24645054) (← links)
- An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study (Q24645469) (← links)
- Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial (Q24793186) (← links)
- The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature (Q26741943) (← links)
- Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives (Q26746239) (← links)
- Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials (Q26773290) (← links)
- The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update (Q26799316) (← links)
- The μ-opioid receptor and treatment response to naltrexone (Q26995866) (← links)
- Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date (Q27014110) (← links)
- Improving clinical outcomes for naltrexone as a management of problem alcohol use (Q27021406) (← links)
- Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans (Q27300685) (← links)
- The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. (Q27310644) (← links)
- Should naltrexone be the first-line medicine to treat alcohol dependence in Aboriginal and Torres Strait Islander populations? An Australian perspective (Q28085051) (← links)
- Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients (Q28196582) (← links)
- A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone (Q28207311) (← links)
- Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation (Q28239922) (← links)
- Low-dose naltrexone therapy improves active Crohn's disease (Q28283321) (← links)
- Acute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice (Q28286555) (← links)
- Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4) (Q28288846) (← links)
- A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis (Q28291875) (← links)
- The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain (Q28307673) (← links)
- Letter: Treatment of accidental naltrexone-induced withdrawal (Q28317877) (← links)